Featured Tickers:
Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Globus Medical, Inc. or NovoCure Limited because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Globus Medical, Inc. and NovoCure Limited compare based on key financial metrics to determine which better meets your investment needs.
About Globus Medical, Inc. and NovoCure Limited
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Latest Health Care Equipment & Supplies and Globus Medical, Inc., NovoCure Limited Stock News
As of March 31, 2025, Globus Medical, Inc. had a $10.1 billion market capitalization, compared to the Health Care Equipment & Supplies median of $260.7 million. Globus Medical, Inc.’s stock is NA in 2025, NA in the previous five trading days and up 37.96% in the past year.
Currently, Globus Medical, Inc.’s price-earnings ratio is 97.6. Globus Medical, Inc.’s trailing 12-month revenue is $2.5 billion with a 4.1% net profit margin. Year-over-year quarterly sales growth most recently was 6.6%. Analysts expect adjusted earnings to reach $3.445 per share for the current fiscal year. Globus Medical, Inc. does not currently pay a dividend.
Currently, NovoCure Limited does not have a price-earnings ratio. NovoCure Limited’s trailing 12-month revenue is $605.2 million with a -27.9% net profit margin. Year-over-year quarterly sales growth most recently was 20.6%. Analysts expect adjusted earnings to reach $-2.045 per share for the current fiscal year. NovoCure Limited does not currently pay a dividend.
How We Compare Globus Medical, Inc. and NovoCure Limited Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Globus Medical, Inc. and NovoCure Limited’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions